A311690 Share Price Performance
Recent A311690 News & Updates
No updates
CJ Bioscience, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.42k
- Gross Margin
- 8.02%
- Net Profit Margin
- -936.05%
- Debt/Equity Ratio
- 9.0%
CJ Bioscience, Inc. Competitors
About A311690
- Founded
- 2009
- Employees
- 137
- CEO
- WebsiteView website
CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics analysis portal for microbial research; EzBioCloud Pro, a next-generation analysis platform for infection diagnosis and microbial bioinformatics analysis; Gut Inside, a microbiome testing service; and TrueBac ID, a cloud-based service platform that can identify various bacterial species based on genomic data. The company was formerly known as ChunLab, Inc. and changed its name to CJ Bioscience, Inc. in December 2021. CJ Bioscience, Inc. was founded in 2009 and is based in Seoul, South Korea.
South Korean Market Performance
- 7 Days: 1.5%
- 3 Months: 24.6%
- 1 Year: 13.5%
- Year to Date: 32.5%
Over the last 7 days, the market has risen 1.5%, driven by gains of 5.3% in the Information Technology sector. As for the past 12 months, the market is up 14%. Looking forward, earnings are forecast to grow by 21% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading